Cooperative effects of INK4a and ras in melanoma susceptibility in vivo

Genes and Development

Volumn 11, Issue 21, 1997, Pages 2822-2834

  Chin, Lynda ^a   Pomerantz, Jason ^a   Polsky, David ^b,c   Jacobson, Mark ^a   Cohen, Carlos ^a   Cordon Cardo, Carlos ^b   Horner II, James W ^a   DePinho, Ronald A ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ink4a; Ink4b; Melanoma; p53; Ras; Transgenic

Indexed keywords

GENE PRODUCT; RAS PROTEIN;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CHROMOSOME 9P; CONTROLLED STUDY; GENE MUTATION; MELANOCYTE; MELANOMA; MOUSE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0030729474     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.11.21.2822     Document Type: Article

References (79)

1. Albino, A.P., R. Le Strange, A.I. Oliff, M.E. Furth, and L.J. Old. 1984. Transforming ras genes from human melanoma: A manifestation of tumour heterogeneity? Nature 308: 69-72.
2. Albino, A.P., D.M. Nanus, I.R. Mentle, C. Cordon-Cardo, N.S. McNutt, J. Bressler, and M. Andreeff. 1989. Analysis of ras oncogenes in malignant melanoma and precursor lesions: Correlation of point mutations with differentiation phenotype. Oncogene 4: 1363-1374.
3. Albino, A.P., G. Sozzi, D.M. Nanus, S.C. Jhanwar, and A.N. Houghton. 1992. Malignant transformation of human melanocytes: Induction of a complete melanoma phenotype and genotype. Oncogene 7: 2315-2321.
4. Auffray, C. and F. Rougeon. 1980. Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA. Eur. J. Biochem. 107: 303-314.
5. Ball, N.J., J.J. Yohn, J.G. Morelli, D.A. Norris, L.E. Golitz, and J.P. Hoeffler. 1994. Ras mutations in human melanoma: A marker of malignant progression. J. Invest. Dermatol. 102: 285-290.
6. Bathia, K., S. Fan, G. Spangler, M. Wintraub, P.M. O'Connor, J.-G. Judde, and I.A. Magrath. 1995. A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma. Cancer Res. 55: 1431-1435.
7. Bradl, M., A. Klein-Szanto, S. Porter, and B. Mintz. 1991. Malignant melanoma in transgenic mice. Proc. Natl. Acad. Sci. 88: 164-168.
8. ARF in breast cancer. Clin. Cancer Res. 2: 1993-1998.
9. Clarke, A.R., E.R. Maandag, M. van Roon, N.M. van der Lugt, M. van der Valk, M.L. Hooper, A. Berns, and H. te Riele. 1992. Requirement for a functional Rb-1 gene in murine development. Nature 359: 328-330.
10. Cordon-Cardo, C. 1995. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am. J. Pathol. 147: 545-560.
11. Davies, R.L., V.A. Grosse, R. Kucherlapati, and M. Bothwell. 1980. Genetic analysis of epidermal growth factor action: Assignment of human epidermal growth factor receptor gene to chromosome 7. Proc. Natl. Acad. Sci. 77: 4188-4192.
12. Cip1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675-684.
13. Elledge, S.J., J. Winston, and J.W. Harper. 1996. A question of balance: The role of cyclin-kinase inhibitors in development and tumorigenesis. Trends Cell Biol. 6: 388-392.
14. Kip1/-deficient mice. Cell 85: 733-744.
15. FitzGerald, M.G., D.P. Harkin, S. Silva-Arrieta, D.J. MacDonald, L.C. Lucchina, H. Unsal, E. O'Neill, J. Koh, D.M. Finkelstein, K.J. Isselbacher et al. 1996. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: Analysis of a clinic-based population. Proc. Natl. Acad. Sci. 93: 8541-8545.
16. Flores, J.F., G.J. Walker, J.M. Glendening, F.G. Haluska, J.S. Castresana, M.P. Rubio, G.C. Pastorfide, L.A. Boyer, W.H. Kao, M.L. Bulyk et al. 1996. Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res. 56: 5023-5032.
17. Ganss, R., L. Montoliu, A.P. Monaghan, and G. Schutz. 1994. A cell-specific enhancer far upstream of the mouse tyrosinase gene confers high level and copy number-related expression in transgenic mice. EMBO J. 13: 3083-3093.
18. Gao, X., Y.Q. Chen, N. Wu, D.J. Grignon, W. Sakr, A.T. Porter, and K.V. Honn. 1995. Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene 11: 1395-1398.
19. Gelsleichter, L., A.M. Gown, R.J. Zarbo, E. Wang, and M.D. Coltrera. 1995. p53 and mdm-2 expression in malignant melanoma: An immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors. Mod. Pathol. 8: 530-535.
20. Glendening, J.M., J.F. Flores, G.J. Walker, S. Stone, A.P. Albino, and J.W. Fountain. 1995. Homozygous loss of the p15INK4b gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient. Cancer Res. 55: 5531-5535.
21. Gorman, C.M., L.F. Moffat, and B.H. Howard. 1982. Recombinant genomes which express chloramphenicol acetyltransrerase in mammalian cells. Mol. Cell. Biol. 2: 1044-1051.
22. Gruis, N.A., P.A. van der Velden, L.A. Sandkuijl, D.E. Prins, J. Weaver-Feldhaus, A. Kamb, W. Bergman, and R.R. Frants. 1995. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nature Genet. 10: 351-353.
23. Hangaishi, A., S. Ogawa, N. Imamura, S. Miyawaki, Y. Miura, N. Uike, C. Shimazaki, N. Emi, K. Takeyama, S. Hirosawa et al. 1996. Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/ p16INK4A/CDKN2, MTS2/p15INK4b, p53, and Rb genes in primary lymphoid malignancies. Blood 87: 4949-4958.
24. Ink4b is a potential effector of cell cycle arrest mediated by TGF-β. Nature 371: 257-261.
25. Harris, C.C. and M. Hollstein. 1993. Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med. 329: 1318-1327.
26. Hayward, N.K. 1996. The current situation with regard to human melanoma and genetic inferences. Curr. Opin. Oncol. 8: 136-142.
27. Heinzel, P.A., P. Balaram, and H.U. Bernard. 1996. Mutations and polymorphisms in the p53, p21 and p16 genes in oral carcinomas of Indian betel quid chewers. Intl. J. Cancer 68: 420-423.
28. Herlyn, M. 1993. Molecular and cellular biology for melanoma. R.G. Landes, Austin, TX.
29. Hirama, T. and H.P. Keoffler. 1995. Role of cyclin-dependent kinase inhibitors in the development of cancer. Blood 86: 841-854.
30. Hogan, B., R. Beddington, F. Costantini, and E. Lacy. 1994. Manipulating the mouse embryo: A laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
31. Hollstein, M., D. Sidransky, B. Vogelstein, and C.C. Harris. 1991. p53 mutations in human cancers. Science 253: 49-53.
32. Huang, T.S., S. Rauth, and T.K. Das Gupta. 1996. Overexpression of EGF receptor is associated with spontaneous metastases of a human melanoma cell line in nude mice. Anticancer Res. 16: 3557-3563.
33. Hussussian, C.J., J.P. Struewing, A.M. Goldstein, P.A. Higgins, D.S. Ally, M.D. Sheahan, W.H. Clark, Jr., M.A. Tucker, and N.C. Dracopoli. 1994. Germline p16 mutations in familial melanoma. Nature Genet. 8: 15-21.
34. Iwamoto, T., M. Takahashi, M. Ito, K. Hamatani, M. Ohbayashi, W. Wajjwalku, K. Isobe, and I. Nakashima. 1991. Aberrant melanogenesis and melanocytic tumour development in transgenic mice that carry a metallothionein/ret fusion gene. EMBO J. 10: 3167-3175.
35. Jacks, T., A. Fazeli, E.M. Schmitt, R.T. Bronson, M.A. Goodell, and R.A. Weinberg. 1992. Effects of an Rb mutation in the mouse. Nature 359: 295-300.
36. Jafari, M., T. Papp, S. Kirchner, U. Diener, D. Henschler, G. Burg, and D. Schiffmann. 1995. Analysis of ras mutations in human melanocytic lesions: Activation of the ras gene seems to be associated with the nodular type of human malignant melanoma. J. Cancer Res. & Clin. Oncol. 121: 23-30.
37. Jen, J., J.W. Harper, S.H. Bigner, D.D. Bigner, N. Papadopoulos, S. Markowitz, J.K.V. Willson, K.W. Kinzler, and B. Vogelstein. 1994. Deletion of p16 and p15 genes in brain tumors. Cancer Res. 54: 6353-6358.
38. Kamb, A. 1995. Cell-cycle regulators and cancer. Trends Genet. 11: 136-140.
39. Kamb, A., N.A. Gruis, J. Weaver-Feldhaus, Q. Liu, K. Harshman, S.V. Tavtigian, E. Stockert, R.S. Day III, B.E. Johnson, and M.H. Skolnick. 1994. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440.
40. Kinoshita, I., H. Dosaka-Akita, T. Mishina, K. Akie, M. Nishi, H. Hiroumi, F. Hommura, and Y. Kawakami. 1996. Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer: Potential synergistic effect with altered p53 protein on proliferative activity. Cancer Res. 56: 5557-5562.
41. KIP1. Cell 85: 721-732.
42. WAF1/CIP in primary bladder tumors. Oncol. Res. 8: 409-414.
43. Land, H., L.F. Parada, and R.A. Weinberg. 1983. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304: 596-602.
44. Lee, E.Y., C.Y. Chang, N. Hu, Y.C. Wang, C.C. Lai, K. Herrup, W.H. Lee, and A. Bradley. 1992. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359: 288-294.
45. Levine, A.J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
46. Lubbe, J., M. Reichel, G. Burg, and P. Kleihues. 1994. Absence of p53 gene mutations in cutaneous melanoma. J. Invest. Dermatol. 102: 819-821.
47. Mangues, R., I. Seidman, A. Pellicer, and J.W. Gordon. 1990. Tumorigenesis and male sterility in transgenic mice expressing a MMTV/N-ras oncogene. Oncogens 5: 1491-1497.
48. Mochizuki, T., G. Wu, T. Hayashi, S.L. Xenophontos, B. Veldhuisen, J.J. Sans, D.M. Reynolds, Y. Cai, P.A. Gabow, A. Pierides et al. 1996. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 272: 1339-1342.
49. Kip1 display increased body size, multiple organ hyperplasia, retinal displasia, and pituitary tumors. Cell 85: 707-720.
50. Newcomb, E.W., L.S. Rao, S.S. Giknavorian, and S.Y. Lee. 1995. Alterations of multiple tumor suppressor genes (p53 (17p13), p16INK4 (9p21), and DBM (13q14)) in B-cell chronic lymphocytic leukemia. Mol. Carcin. 14: 141-146.
51. Orlow, I., L. Lacombe, G.J. Hannon, M. Serrano, G. Dalbagni, I. Pellicer, V.E. Reuter, Z.-F. Zhang, D. Beach, and C. Cordon-Cardo. 1995. Deletion of the p16 and p15 genes in human bladder tumors. J. Natl. Cancer Inst. 87: 1524-1529.
52. Orlow, I., A. Iavarone, S.J. Crider-Miller, F. Bonilla, E. Latres, M.H. Lee, W.L. Gerald, J. Massague, B.E. Weissman, and C. Cordon-Cardo. 1996. Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms' tumors. Cancer Res. 56: 1219-1221.
53. Papp, T., M. Jafari, and D. Schiffmann. 1996. Lack of p53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions. J. Cancer Res. & Clin. Oncol. 122: 541-548.
54. Poremba, C., D.W. Yandell, D. Metze, D. Kamanabrou, W. Bocker, and B. Dockhorn-Dworniczak. 1995. Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression. Oncol. Res. 7: 331-339.
55. Powell, M.B., P. Hyman, O.D. Bell, A. Balmain, K. Brown, D. Alberts, and G.T. Bowden. 1995. Hyperpigmentation and melanocytic hyperplasia in transgenic mice expressing the human T24 Ha-ras gene regulated by a mouse tyrosinase promoter. Mol. Carcin. 12: 82-90.
56. INK4b genes. Oncogene 11: 635-645.
57. Quelle, D.E., F. Zindy, R.A. Ashmun, and C.J. Sherr. 1995b. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000.
58. Quelle, D.E., M. Cheng, R.A. Ashmun, and C.J. Sherr. 1997. Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. Proc. Natl. Acad. Sci. 94: 669-673.
59. Quesnel, B., C. Preudhomme, and P. Fenaux. 1996. p16ink4a gene and hematological malignancies. Leukem. & Lymphom. 22: 11-24.
60. Ramon y Cajal, S., S. Suster, R. Halaban, E. Filvaroff, and G.P. Dotto. 1991. Induction of different morphologic features of malignant melanoma and pigmented lesions after transformation of murine melanocytes with bFGF-cDNA and H-ras, myc, neu, and E1a oncogenes. Am. J. Pathol. 138: 349-358.
61. Rigel, D.S., R.J. Friedman, and A.W. Kopf. 1996. Lifetime risk for development of skin cancer in the U.S. population: Current estimate is now 1 in 5. J. Am. Acad. Dermatol. 35: 1012-1013.
62. Sambrook, J., E.F. Fritsch, and T. Maniatis. 1989. Molecular cloning: A laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
63. Serrano, M., G.J. Hannon, and D. Beach. 1993. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/cdk4. Nature 366: 704-707.
64. Serrano, M., H. Lee, L. Chin, C. Cordon-Cardo, D. Beach, and R.A. DePinho. 1996. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85: 27-37.
65. Serrano, M., A.W. Lin, M.E. McCurrach, D. Beach, and S.W. Lowe. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593-602.
66. Spirin, K.S., J.F. Simpson, S. Takeuchi, N. Kawamata, W.M. Willer, and H.P. Koeffler. 1996. p27/Kip1 mutation found in breast cancer. Cancer Res. 56: 2400-2404.
67. Steel, K.P. and C. Barkway. 1989. Another role for melanocytes: Their importance for normal stria vascularis development in the mammalian inner ear. Development 107: 453-463.
68. Stone, S., P. Jiang, P. Dayananth, S.V. Tavtigian, H. Katcher, D. Parry, G. Peters, and A. Kamb. 1995. Complex structure and regulation of the p16(MTS1) locus. Cancer Res. 55: 2988-2994.
69. Takayama, H., W.J. LaRochelle, R. Sharp, T. Otsuka, P. Kriebel, M. Anver, S.A. Aaronson, and G. Merlino. 1997. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc. Natl. Acad. Sci. 94: 701-706.
70. Tan, T.H., J. Wallis, and A.J. Levine. 1986. Identification of the p53 protein domain involved in formation of the simian virus 40 large T-antigen-p53 protein complex. J. Virol. 59: 574-583.
71. Thomson, T.M., F.X. Real, S. Murakami, C. Cordon-Cardo, L.J. Old, and A.N. Houghton. 1988. Differentiation antigens of melanocytes and melanoma: Analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. J. Invest. Dermatol. 90: 459-466.
72. Tremblay, P.J., F. Pothier, T. Hoang, G. Tremblay, S. Brownstein, A. Liszauer, and P. Jolicoeur. 1989. Transgenic mice carrying the mouse mammary tumor virus ras fusion gene: Distinct effects in various tissues. Mol. Cell. Biol. 9: 854-859.
73. van 't Veer, L.J., B.M. Burgering, R. Versteeg, A.J. Boot, D.J. Ruiter, S. Osanto, P.I. Schrier, and J.L. Bos. 1989. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol. Cell. Biol. 9: 3114-3116.
74. Van Dyke, TA. 1994. Analysis of viral-host protein interactions and tumorigenesis in transgenic mice. Semin. Cancer Biol. 5: 47-60.
75. Vidai, M., F. Loganzo, Jr., A.R. de Oliveira, N.K. Hayward, and A.P. Albino. 1995. Mutations and defective expression of the WAF1 p21 tumour-suppressor gene in malignant melanomas. Melanoma Res. 5: 243-250.
76. Wagner, S.N., H.M. Ockenfels, C. Wagner, H. Hofler, and M. Goos. 1995. Ras gene mutations: A rare event in nonmetastatic primary malignant melanoma. J. Invest. Dermatol. 104: 868-871.
77. Wilson, R.E., T.P. Dooley, and I.R. Hart. 1989. Induction of tumorigenicity and lack of in vitro growth requirement for 12-O-tetradecanoylphorbol-13-acetate by transfection of murine melanocytes with v-Ha-ras. Cancel Res. 49: 711-716.
78. Wittbrodt, J., R. Lammers, B. Malitschek, A. Ullrich, and M. Schartl. 1992. The Xmrk receptor tyrosine kinase is activated in Xiphophorus malignant melanoma. EMBO J. 11: 4239-4246.
79. Yasuda, H., H. Kobayashi, A. Ohkawara, and N. Kuzumaki. 1989. Differential expression of ras oncogene products among the types of human melanomas and melanocytic nevi. J. Invest. Dermatol. 93: 54-59.